Top

Published in:

01-04-2008 | Review

Syndecan-1: a dynamic regulator of the myeloma microenvironment

Authors: Ralph D. Sanderson, Yang Yang

Published in: Clinical & Experimental Metastasis | Issue 2/2008

Abstract

Emerging data in myeloma and other cancers indicates that heparan sulfate proteoglycans promote tumor progression by enhancing their growth and metastasis. By acting as key regulators of cell signaling via their interactions with multiple growth and angiogenic factors, heparan sulfates mediate a shift in the microenvironment that supports the tumor as an ‘organ’ and promotes an aggressive tumor phenotype. In addition, enzymatic remodeling of heparan sulfate proteoglycans provides a mechanism for rapid, localized and dynamic modulation of proteoglycan function thereby tightly regulating activities within the tumor microenvironment. New data from animal models demonstrates that heparan sulfate or the enzymes that regulate heparan sulfate are viable targets for cancer therapy. This strategy of targeting heparan sulfate may be particularly effective for attacking cancers like myeloma where extensive genetic chaos renders them unlikely to respond well to agents that target a single signaling pathway.

Bernfield M, Gotte M, Park PW et al (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729–777PubMed

Lander AD, Selleck SB (2000) The elusive functions of proteoglycans: in vivo veritas. J Cell Biol 148(2):227–232PubMed

Woods A, Couchman JR (1998) Syndecans: synergistic activators of cell adhesion. Trends Cell Biol 8(5):189–192PubMed

Iozzo RV, San Antonio JD (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108(3):349–355PubMed

Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446(7139):1030–1037PubMed

Goger B, Halden Y, Rek A et al (2002) Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 41(5):1640–1646PubMed

Filla MS, Dam P, Rapraeger AC (1998) The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 174(3):310–321PubMed

Perrimon N, Bernfield M (2001) Cellular functions of proteoglycans–an overview. Semin Cell Dev Biol 12(2):65–67PubMed

Sasisekharan R, Shriver Z, Venkataraman G et al (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2(7):521–528PubMed

10.

Blackhall FH, Merry CL, Davies EJ et al (2001) Heparan sulfate proteoglycans and cancer. Br J Cancer 85(8):1094–1098PubMed

11.

Fears CY, Woods A (2006) The role of syndecans in disease and wound healing. Matrix Biol 25(7):443–456PubMed

12.

Beauvais DM, Rapraeger AC (2004) Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2(1):3PubMed

13.

Esko JD, Rostand KS, Weinke JL (1988) Tumor formation dependent on proteoglycan biosynthesis. Science 241(4869):1092–1096PubMed

14.

Alexander CM, Reichsman F, Hinkes MT et al (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25(3):329–332PubMed

15.

Perrimon N, Bernfield M (2000) Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404(6779):725–728PubMed

16.

Capurro MI, Xiang YY, Lobe C et al (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65(14):6245–6254PubMed

17.

Sharma B, Handler M, Eichstetter I et al (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102(8):1599–1608PubMed

18.

Mathiak M, Yenisey C, Grant DS et al (1997) A role for perlecan in the suppression of growth and invasion in fibrocarcinoma cells. Cancer Res 57(11):2130–2136PubMed

19.

Savore C, Zhang C, Muir C et al (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22(5):377–390PubMed

20.

Dhodapkar MV, Kelly T, Theus A et al (1997) Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Hematol 99:368–371

21.

Joensuu H, Anttonen A, Eriksson M et al (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62(18):5210–5217PubMed

22.

Kleeff J, Ishiwata T, Kumbasar A et al (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102(9):1662–1673PubMedCrossRef

23.

Matsuda K, Maruyama H, Guo F et al (2001) Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61(14):5562–5569PubMed

24.

Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12(2):89–98PubMed

25.

Yu WH, Woessner JF Jr (2000) Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 275(6):4183–4191PubMed

26.

Liebersbach BF, Sanderson RD (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269:20013–20019PubMed

27.

Borsig L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98(6):3352–3357PubMed

28.

Turnbull J, Powell A, Guimond S (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11(2):75–82PubMed

29.

Selleck SB (2000) Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet 16(5):206–212PubMed

30.

Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108(3):357–361PubMed

31.

Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273(39):24979–24982PubMed

32.

Sasisekharan R, Venkataraman G (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4(6):626–631PubMed

33.

Underhill CB, Keller JM (1975) A transformation-dependent difference in the heparan sulfate associated with the cell surface. Biochem Biophys Res Commun 63:448–454PubMed

34.

Winterbourne DJ, Mora PT (1978) Altered metabolism of heparan sulphate in simian virus 40 transformed cloned mouse cells. J Biol Chem 253:5109–5120PubMed

35.

David G, Van Den Berghe H (1983) Transformed mouse mammary epithelial cells synthesize undersulfated basement membrane proteoglycan. J Biol Chem 258(12):7338–7344PubMed

36.

Robinson J, Viti M, Höök M (1984) Structure and properties of an under-sulfated heparan sulfate proteoglycan synthesized by a rat hepatoma cell line. J Cell Biol 98:946–953PubMed

37.

Sanderson RD, Turnbull JE, Gallagher JT et al (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269(18):13100–13106PubMed

38.

Jayson GC, Lyon M, Paraskeva C et al (1998) Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 273(1):51–57PubMed

39.

Safaiyan F, Lindahl U, Salmivirta M (1998) Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem 252(3):576–582PubMed

40.

Vlodavsky I, Friedmann Y, Elkin M et al (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5(7):793–802PubMed

41.

Kussie PH, Hulmes JD, Ludwig DL et al (1999) Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 261(1):183–187PubMed

42.

Hulett MD, Freeman C, Hamdorf BJ et al (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5(7):803–809PubMed

43.

Toyoshima M, Nakajima M (1999) Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 274(34):24153–24160PubMed

44.

Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108(3):341–347PubMed

45.

Bitan M, Polliack A, Zecchina G et al (2002) Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp Hematol 30(1):34–41PubMed

46.

Kato M, Wang H, Kainulainen V et al (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4(6):691–697PubMed

47.

Vlodavsky I, Goldshmidt O, Zcharia E et al (2002) Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 12(2):121–129PubMed

48.

Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38(12):2018–2039PubMed

49.

Whitelock JM, Murdoch AD, Iozzo RV et al (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–10086PubMed

50.

Elkin M, Ilan N, Ishai-Michaeli R et al (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15(9):1661–1663PubMed

51.

Vreys V, Delande N, Zhang Z et al (2005) Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280(39):33141–33148PubMed

52.

Cohen T, Gitay-Goren H, Sharon R et al (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270(19):11322–11326PubMed

53.

Gitay-Goren H, Soker S, Vlodavsky I et al (1992) The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267(9):6093–6098PubMed

54.

Chiang MK, Flanagan JG (1995) Interactions between the Flk-1 receptor, vascular endothelial growth factor, and cell surface proteoglycan identified with a soluble receptor reagent. Growth Factors 12(1):1–10PubMed

55.

Dougher AM, Wasserstrom H, Torley L et al (1997) Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 14(4):257–268PubMed

56.

Fuster MM, Wang L, Castagnola J et al (2007) Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol 177(3):539–549PubMed

57.

Ruhrberg C, Gerhardt H, Golding M et al (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16(20):2684–2698PubMed

58.

Gengrinovitch S, Berman B, David G et al (1999) Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274(16):10816–10822PubMed

59.

Ai X, Do AT, Lozynska O et al (2003) QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 162(2):341–351PubMed

60.

Dhoot GK, Gustafsson MK, Ai X et al (2001) Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293(5535):1663–1666PubMed

61.

Morimoto-Tomita M, Uchimura K, Werb Z et al (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277(51):49175–49185PubMed

62.

Lai JP, Chien J, Strome SE et al (2004) HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23(7):1439–1447PubMed

63.

Uchimura K, Morimoto-Tomita M, Bistrup A et al (2006) HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 7:2PubMed

64.

Morimoto-Tomita M, Uchimura K, Bistrup A et al (2005) Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7(11):1001–1010PubMed

65.

Narita K, Chien J, Mullany SA et al (2007) Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 282(19):14413–14420PubMed

66.

Staub J, Chien J, Pan Y et al (2007) Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26(34):4969–4978PubMed

67.

Lai JP, Chien JR, Moser DR et al (2004) hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126(1):231–248PubMed

68.

Dai Y, Yang Y, MacLeod V et al (2005) HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280(48):40066–40073PubMed

69.

Jalkanen M, Rapraeger A, Saunders S et al (1987) Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. J Cell Biol 105:3087–3096PubMed

70.

Sanderson RD, Yang Y, Suva LJ et al (2004) Heparan sulfate proteoglycans and heparanase–partners in osteolytic tumor growth and metastasis. Matrix Biol 23(6):341–352PubMed

71.

Li Q, Park PW, Wilson CL et al (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111(5):635–646PubMed

72.

Capurro M, Wanless IR, Sherman M et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89–97PubMed

73.

Nakatsura T, Kageshita T, Ito S et al (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10(19):6612–6621PubMed

74.

Nakatsura T, Nishimura Y (2005) Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19(2):71–77PubMed

75.

Seidel C, Sundan A, Hjorth M et al (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95(2):388–392PubMed

76.

Liu D, Shriver Z, Venkataraman G et al (2002) Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99(2):568–573PubMed

77.

Ernst S, Langer R, Cooney CL et al (1995) Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 30(5):387–444PubMed

78.

Bergsagel D (1995) The incidence and epidemiology of plasma cell neoplasms. Stem Cells 13(Suppl 2):1–9PubMed

79.

Barlogie B, Shaughnessy J, Epstein J et al (2006) Plasma cell myeloma. In: Lichtman MA, Beutler E, Kipps TJ et al (eds) Williams hematology, 7th edn. McGraw-Hill, New York

80.

Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2(3):175–187PubMed

81.

Anderson KC (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35(4 Suppl 1):155–162PubMed

82.

Mundy GR (1998) Myeloma bone disease. Eur J Cancer 34(2):246–251PubMed

83.

Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32(2):290–292PubMed

84.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593PubMed

85.

Ridley RC, Xiao H, Hata H et al (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81(3):767–774PubMed

86.

Wijdenes J, Vooijs WC, Clement C et al (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94(2):318–323PubMed

87.

Chilosi M, Adami F, Lestani M et al (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12(12):1101–1106PubMed

88.

Bayer-Garner IB, Sanderson RD, Dhodapkar MV et al (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14(10):1052–1058PubMed

89.

Witzig TE, Kimlinger T, Stenson M et al (1998) Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31(1–2):167–175PubMed

90.

Sanderson RD, Lalor P, Bernfield M (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1(1):27–35PubMed

91.

Zhan F, Tian E, Bumm K et al (2003) Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101(3):1128–1140PubMed

92.

Tassone P, Goldmacher VS, Neri P et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104(12):3688–3696PubMed

93.

Post J, Vooijs WC, Bast BJ et al (1999) Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int J Cancer 83(4):571–576PubMed

94.

Ragnarsson L, Stromberg T, Wijdenes J et al (2001) Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol Immunother 50(7):382–390PubMed

95.

von Strandmann EP, Hansen HP, Reiners KS et al (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107(5):1955–1962

96.

Dhodapkar KM, Krasovsky J, Williamson B et al (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195(1):125–133PubMed

97.

Zimmermann P, Tomatis D, Rosas M et al (2001) Characterization of syntenin, a syndecan-binding PDZ protein, as a component of cell adhesion sites and microfilaments. Mol Biol Cell 12(2):339–350PubMed

98.

Couchman JR, Chen L, Woods A (2001) Syndecans and cell adhesion. Int Rev Cytol 207:113–150PubMed

99.

Beauvais DM, Burbach BJ, Rapraeger AC (2004) The syndecan-1 ectodomain regulates alpha V beta 3 integrin activity in human mammary carcinoma cells. J Cell Biol 167(1):171–181PubMed

100.

McQuade KJ, Beauvais DM, Burbach BJ et al (2006) Syndecan-1 regulates alpha V beta5 integrin activity in B82L fibroblasts. J Cell Sci 119(Pt 12):2445–2456PubMed

101.

Sanderson RD, Hinkes MT, Bernfield M (1992) Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratify. J Invest Dermatol 99(4):390–396PubMed

102.

Stanley MJ, Liebersbach BF, Liu W et al (1995) Heparan sulfate-mediated cell aggregation: Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem 270:5077–5083PubMed

103.

Subramanian SV, Fitzgerald ML, Bernfield M (1997) Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272(23):14713–14720PubMed

104.

Fitzgerald ML, Wang Z, Park PW et al (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148(4):811–824PubMed

105.

Jourdan M, Ferlin M, Legouffe E et al (1998) The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100(4):637–646PubMed

106.

Lovell R, Dunn JA, Begum G et al (2005) Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol 130(4):542–548PubMed

107.

Yang Y, Yaccoby S, Liu W et al (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100(2):610–617PubMed

108.

Andersen NF, Standal T, Nielsen JL et al (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128(2):210–217PubMed

109.

Su G, Blaine SA, Qiao D et al (2007) Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 282(20):14906–14915PubMed

110.

Maeda T, Desouky J, Friedl A (2006) Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25(9):1408–1412PubMed

111.

Endo K, Takino T, Miyamori H et al (2003) Cleavage of syndecan-1 by membrane-type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278:40764–40770PubMed

112.

Brule S, Charnaux N, Sutton A et al (2006) The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16(6):488–501PubMed

113.

Holen I, Drury NL, Hargreaves PG et al (2001) Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol 114(2):414–421PubMed

114.

Kelly T, Miao HQ, Yang Y et al (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63(24):8749–8756PubMed

115.

Yang Y, Macleod V, Bendre M et al (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105(3):1303–1309PubMed

116.

Kelly T, Suva LJ, Huang Y et al (2005) Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65(13):5778–5784PubMed

117.

Yang Y, Macleod V, Miao HQ et al (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282(18):13326–13333PubMed

118.

Mahtouk K, Hose D, Raynaud P et al (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109(11):4914–4923PubMed

119.

Roodman GD (2002) Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17(11):1921–1925PubMed

120.

Anderson KC, Dalton WS (2002) Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis–opportunities for new drug discovery. Mol Cancer Ther 1(14):1361–1365PubMed

121.

Zhan F, Hardin J, Kordsmeier B et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757PubMed

122.

Tarte K, Zhan F, De Vos J et al (2003) Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102(2):592–600PubMed

123.

Derksen PW, Keehnen RM, Evers LM et al (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99(4):1405–1410PubMed

124.

Seidel C, Borset M, Hjertner O et al (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96(9):3139–3146PubMed

125.

Standal T, Seidel C, Hjertner O et al (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100(8):3002–3007PubMed

126.

Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165–176PubMed

127.

Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108(6):2020–2028PubMed

128.

Yang Y, MacLeod V, Dai Y et al (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110(6):2041–2048PubMed

129.

Naggi A, Casu B, Perez M et al (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280(13):12103–12113PubMed

Title: Syndecan-1: a dynamic regulator of the myeloma microenvironment
Authors: Ralph D. Sanderson
Yang Yang
Publication date: 01-04-2008
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 2/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-007-9125-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

The tumor cell–host organ interface in the early onset of metastatic organ colonisation

Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth

Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer